# A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

> **NCT04516291** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 286 (actual)

## Conditions studied

- Dyslipidemias
- Hyperlipidemias
- Hyperlipoproteinemias

## Interventions

- **DRUG:** Vupanorsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04516291
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-12-06
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516291, "A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04516291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*